11 therapies have outgrown the IPM growth and have double digit growths
The Indian Pharma Market (IPM) clocked Rs 7243 crores in November 2014 and has grown at 10.9 per cent. Amongst the top 10, Pfizer grew by 34.1 per cent followed by Ranbaxy at 23.1 per cent and Sun Pharma at 14.9 per cent. 21 corporates have crossed the growth of IPM amongst top 50.
Amongst the top 50 corporate, Akumentis has the highest growth of 68 per cent followed by Pfizer at 34.1 per cent and Ajanta at 33.1 per cent. 24 corporates have shown growths more than 10 per cent amongst the top 50.
Amongst the 11-20 ranked corporates, Macleods has the highest growth of 24.6 per cent followed by Torrent at 23.3 per cent and Glenmark at 20.3 per cent. Amongst the 51-60 ranked corporates, Panacea grows at 31.3 per cent followed by Pharmed at 25.6 per cent and Corona at 21.9 per cent.
|
With Bonus Units at Full Value
|
||||||||
|
Val in Crs
|
Rank
|
MAT Nov -14
|
Nov-14
|
|||||
|
CORPORATE
|
MAT
|
MTH
|
Val (Cr)
|
MS%
|
GR%
|
Val (Cr)
|
MS%
|
GR%
|
| IPM |
82095
|
100.00
|
9.9
|
7243
|
100.00
|
10.9
|
||
| Abbott + Abbott HC + Novo |
1
|
1
|
5067
|
6.17
|
6.2
|
449
|
6.20
|
10.2
|
| Sun Pharma |
2
|
2
|
4449
|
5.42
|
14.8
|
411
|
5.67
|
14.9
|
| Cipla |
3
|
3
|
4099
|
4.99
|
11.0
|
355
|
4.90
|
8.3
|
| Zydus + Biochem |
4
|
4
|
3565
|
4.34
|
7.9
|
317
|
4.38
|
7.4
|
| Ranbaxy |
5
|
5
|
2993
|
3.65
|
8.7
|
297
|
4.10
|
23.1
|
| Mankind |
6
|
6
|
2949
|
3.59
|
11.7
|
259
|
3.58
|
11.6
|
| Alkem + Cachet + Indchemie |
7
|
7
|
2903
|
3.54
|
12.5
|
255
|
3.52
|
5.6
|
| GSK |
8
|
9
|
2777
|
3.38
|
-5.2
|
235
|
3.24
|
5.7
|
| Lupin |
9
|
8
|
2740
|
3.34
|
12.2
|
238
|
3.29
|
8.2
|
| Pfizer |
10
|
10
|
2426
|
2.95
|
11.6
|
223
|
3.08
|
34.1
|
| Macleods |
11
|
11
|
2356
|
2.87
|
24.9
|
209
|
2.88
|
24.6
|
| Emcure + Zuventus |
12
|
13
|
2215
|
2.70
|
9.1
|
191
|
2.63
|
7.3
|
| Intas |
13
|
12
|
2147
|
2.61
|
15.5
|
192
|
2.66
|
16.2
|
| Aristo |
14
|
15
|
2052
|
2.50
|
19.3
|
178
|
2.46
|
7.6
|
| Sanofi India |
15
|
14
|
2030
|
2.47
|
3.8
|
188
|
2.60
|
18.2
|
| Torrent |
16
|
17
|
1820
|
2.22
|
7.9
|
168
|
2.32
|
23.3
|
| Glenmark |
17
|
16
|
1788
|
2.18
|
15.0
|
177
|
2.45
|
20.3
|
| Dr Reddys |
18
|
18
|
1748
|
2.13
|
9.2
|
152
|
2.10
|
9.4
|
| Micro + Bal |
19
|
20
|
1602
|
1.95
|
8.3
|
136
|
1.88
|
3.2
|
| USV |
20
|
19
|
1580
|
1.92
|
15.7
|
142
|
1.95
|
15.0
|
| Ipca |
21
|
21
|
1474
|
1.80
|
20.7
|
124
|
1.71
|
4.2
|
| Novartis |
22
|
23
|
1154
|
1.41
|
1.0
|
97
|
1.33
|
5.2
|
Amongst the 61-75 ranked Corporate, Boehringer grew by 83.5 per cent followed by TTK at 18 per cent and RPG at 16.3 per cent. Merck entered the Rs 500-crore club and Albert David in the Rs 300-crore Club as on MAT November 2014. Indian companies have grown at 9.5 per cent versus 14.9 per cent for MNCs in November 2014.
Amongst the top 50 in MNCs, Pfizer grew by 34.1 per cent followed by Merck at 24.5 per cent and Ranbaxy at 23.1 per cent. Under the non-NLEM category, Indian companies grew at 0.4 per cent whereas MNCs grew at 11.1 per cent.
The DPCO containing molecules market grew at 3.1 per cent whereas the non DPCO market grew by 12.6 per cent resulting in an overall growth of 10.9 per cent for November 2014. NLEM and non-NLEM category showed unit growth at -3.4 per cent and 0.3 per cent respectively. The DPCO 2013 portfolio for Pfizer grew at 20.9 per cent, GSK -1.5 per cent, Ranbaxy 34.3 per cent.
|
Val in Crs
|
MAT Nov 14
|
Month Nov-14
|
||
|
Super Group
|
Val in Crs
|
VAL GR%
|
Val in Crs
|
VAL GR%
|
| IPM |
82095
|
9.9
|
7243
|
10.9
|
| ANTI-INFECTIVES |
13198
|
5.7
|
1151
|
4.0
|
| CARDIAC |
10162
|
9.8
|
894
|
12.8
|
| GASTRO INTESTINAL |
9438
|
11.3
|
794
|
12.8
|
| VITAMINS / MINERALS / NUTRIENTS |
7425
|
10.9
|
640
|
13.9
|
| RESPIRATORY |
6337
|
11.1
|
616
|
4.1
|
| ANTI DIABETIC |
6124
|
20.0
|
559
|
23.8
|
| PAIN / ANALGESICS |
5893
|
9.0
|
511
|
8.1
|
| NEURO / CNS |
5103
|
7.8
|
450
|
11.2
|
| DERMA |
4701
|
16.0
|
445
|
19.3
|
| GYNAECOLOGICAL |
4176
|
4.5
|
348
|
7.9
|
| OPHTHAL / OTOLOGICALS |
1522
|
13.4
|
136
|
19.7
|
| ANTI-NEOPLASTICS |
1346
|
26.8
|
110
|
15.1
|
| HORMONES |
1344
|
4.8
|
118
|
8.7
|
| VACCINES |
1173
|
-7.3
|
96
|
-0.1
|
| BLOOD RELATED |
979
|
2.1
|
79
|
4.6
|
| OTHERS |
900
|
9.8
|
87
|
25.2
|
| UROLOGY |
858
|
20.2
|
78
|
28.3
|
| ANTI MALARIALS |
598
|
5.8
|
57
|
-7.5
|
| SEX STIMULANTS / REJUVENATORS |
458
|
3.4
|
42
|
8.7
|
| STOMATOLOGICALS |
358
|
11.8
|
31
|
13.7
|
From therapy perspective, 11 therapies have outgrown the IPM growth and have double digit growths. The respiratory market grew at 4.1 per cent, gastrointestinal market grew at 12.8 per cent, pain and analgesics market grew at 8.1 per cent whereas the anti-infectives grew at four per cent. The anti-diabetic market grows at 23.8 per cent and cardiac at 12.8 per cent in chronic business. The derma market grew by 19.3 per cent and the urology market at 28.3 per cent.
From regional perspective, 14 regions have outgrown the IPM growth. The Gujarat market grew the highest at 22.4 per cent followed by Chattisgarh market at 19.6 per cent and Madhya Pradesh market at 19.3 per cent. No regions had negative growth in November 2014.
Amoxycillin + Clavulanic acid market degrows at -1.4 per cent whereas Glimepiride + Metformin grows at 12.1 per cent at number two. The markets of paracetamol grew at two per cent, atorvastatin 18.2 per cent, probiotic microbes at 30.6 per cent, cefixime -2.2 per cent, pantoprazole 15 per cent, montelukast + levocetrizine at 13 per cent, glimepiride + metformin + pioglitazone at 25.2 per cent, vitamin-D at 35.7 per cent, hydroquinone + mometasone + tretinoin at 32 per cent, voglibose + metformin + glimepiride at 53.8 per cent, leveteracetam at 26.4 per cent, protein supplements at 22.7 per cent.
Mixtard continues to lead the pack with Rs 31.1 crores for the month of November14 with a growth of 16.7 per cent. Lantus grew at 41.2 per cent, glycomet- GP grows at 21.9 per cent, monocef grows at 10.2 per cent, augmentin grows at 3.2 per cent, amongst the top 10 brands.
Amongst the brands who have gained ranks include Glycomet-GP (+6), Lantus (+13), Dexorange (+3), Liv-52 (+7), Galvus Met (+12), Skinlite (+14), Pan (+19), Zincovit (+6), Thyronorm (+30), Pan D (+13), Shelcal (+78), Janumet (+84), Panderm Plus (+64), Levipil (+20) amongst top 100 brands over November 13
A total of 379 SKUs and 239 brands were launched in November 2014. Top new brands for November are Janumet XR CP, Bio Exidil & Celekast.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net